Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer

Journal of Urology

Volumn 171, Issue 4, 2004, Pages 1537-1542

  Reed, Shelby D ^a   Radeva, Jasmina I ^a   Glendenning, G Alastair ^b   Saad, Fred ^c   Schulman, Kevin A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOTRE DAME HOSPITAL   (Canada)

Author keywords

Bone and bones; Cost benefit analysis; Prostate; Prostatic neoplasms; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COST; DRUG EFFICACY; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

EID: 1642386897     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000116777.94426.60     Document Type: Article

References (16)

1. Carlin, B. I. and Andriole, G. L.: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer, suppl., 88: 2989, 2000
2. Berruti, A., Dogliotti, L., Bitossi, R., Fasolis, G., Gorzegno, G., Bellina, M. et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol, 164: 1248, 2000
3. Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J. et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7: 377, 2001
4. Coleman, R. E., Rosen, L. S., Gordon, D., Major, P., Kaminski, M., Apffelstaedt, J. et al: Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis. Presented at 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 11-14, 2002
5. Saad, F., Gleason, D. M., Murray, R., Tchekedyian, S., Venner, P., Lacombe, L. et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone -refractory metastatic prostate carcinoma. J Natl Cancer Inst, 94: 1458, 2002
6. Hillner, B. E., Weeks, J. C., Desch, C. E. and Smith, T. J.: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol, 18: 72, 2000
7. Dranitsaris, G. and Hsu, T.: Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer, 7: 271, 1999
8. Hillner, B. E.: Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin Oncol, suppl., 28: 64, 2001
9. Body, J. J.: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer, suppl., 97: 859, 2003
10. Schulman, K., Burke, J., Drummond, M., Davies, L., Carlsson, P., Gruger, J. et al: Resource costing for multinational neurologic clinical trials: methods and results. Health Econ, 7: 629, 1998
11. Reed, S. D., Friedman, J. Y., Gnanasakthy, A. and Schulman, K. A.: A comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care, 19: 396, 2003
12. Pharmacy Benefits Management, Strategic Health Group. Department of Veterans Affairs. Available at http://www.vapbm. org/PBM/natform.htm. Accessed March 26, 2003
13. DesHarnais Castel, L., Bajwa, K., Markle,J. P., Timbie, J. W., Zacker, C. and Schulman, K. A.: A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer, 9: 545, 2001
14. Efron, B. and Tibshirani, R. J.: Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci, 1: 54, 1986
15. Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C. et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med, 335: 1785, 1996
16. Groot, M. T., Boeken Kruger, C. G., Pelger, R. C. and Uyl-de Groot, C. A.: Costs of prostate cancer, metastatic to the bone in the Netherlands. Eur Urol, 43: 226, 2003